MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is Veradigm (MDRX) Poised for a Comeback After Its Tumultuous Journey

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Desktop Metal's Tumultuous Journey: From Hype to Bankruptcy – What Happened

2 months ago

Is J.M. Smucker (SJM) Poised for a Comeback in 2026

5 months ago

Has Sleep Number Finally Found Its Footing After a Tumultuous Period

5 months ago

What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey

4 months ago

EverCommerce (EVCM) Moves 5.4% Higher: Will This Strength Last?

EverCommerce (EVCM) shares rose 5.4% on above-average volume, but recent earnings estimate revisions suggest limited near-term upside.

EVCM

Stock News•1 months ago

Wall Street Analysts Think VAREX IMAGING (VREX) Could Surge 61.6%: Read This Before Placing a Bet

VREX consensus price target implies 61.6% upside, though empirical data shows such targets are unreliable. An upward trend in earnings estimate revisions could support near-term gains.

VREX

Stock News•1 months ago

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal (MDGL) fell 7.9% since its last earnings report 30 days ago, as investors assess the outlook for its lead drug Rezdiffra.

MDGL

Stock News•2 months ago

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround

Atea Pharmaceuticals (AVIR) shares fell 25% over the past four weeks, signaling potential exhaustion of selling pressure. Analysts have recently revised earnings estimates higher, suggesting a possibl...

AVIR